checkAd

     585  0 Kommentare AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference - Seite 2

    CONTACT

    Galapagos NV
    Elizabeth Goodwin, Head of Corporate Communications & IR
    Tel: +31 6 2291 6240
    ir@glpg.com

    Galapagos forward-looking statements
    This release may contain forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," "continues," "we believe," "we intend," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements and estimating the commercial potential of our product candidates.  A further list and description of these risks, uncertainties and other risks can be found in the company's Securities and Exchange Commission filing and reports, including in the company's prospectus filed with the SEC on May 14, 2015 and future filings and reports by the company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.





    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Galapagos NV via Globenewswire

    HUG#1928322
    Seite 2 von 2



    Diskutieren Sie über die enthaltenen Werte



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference - Seite 2 Mechelen, Belgium; 15 June 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced a joint presentation with AbbVie (NYSE: ABBV) at the 38th annual European Cystic Fibrosis Society conference in Brussels, Belgium. "Development of Trafficking Assays …